Catalyst Wire Dossier Catalyst Wire Dossier

Bimatoprost 0.01% (LUMIGAN)

Bimatoprost · Allergan
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bimatoprost 0.01% (LUMIGAN), covering 2013-09-04 to 2013-09-04. Get the full timeline:

Most recent: Clinical Trial Update: Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) [Phase 4]

See pricing